Table Of Contents

1 Introduction	6
1.1 Industry Definition and Research Scope	6
1.1.1 Industry Definition	6
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of North America Market by Service	41
3.1 Market Overview by Service	41
3.2 Genotyping	43
3.3 SNP Identification	44
3.4 Diagnostics	45
3.5 Other Services	47
4 Segmentation of North America Market by Technology	48
4.1 Market Overview by Technology	48
4.2 Polymerase Chain Reaction (PCR)	50
4.3 Microarray	51
4.4 Sequencing	52
4.5 Electrophoresis	53
4.6 Mass Spectrometry	54
4.7 Other Technologies	55
5 Segmentation of North America Market by Application	56
5.1 Market Overview by Application	56
5.2 Oncology	58
5.3 Infectious Diseases	59
5.4 Neurology/Psychiatry	60
5.5 Cardiovascular	62
5.6 Pain Management	63
5.7 Other Applications	64
6 Segmentation of North America Market by End User	65
6.1 Market Overview by End User	65
6.2 Hospitals and Clinics	67
6.3 Pharmaceutical Companies	68
6.4 Research Institutes	69
7 North America Market 2019-2030 by Country	70
7.1 Overview of North America Market	70
7.2 U.S.	73
7.3 Canada	77
7.4 Mexico	79
8 Competitive Landscape	81
8.1 Overview of Key Vendors	81
8.2 New Product Launch, Partnership, Investment, and M&A	85
8.3 Company Profiles	86
23andMe, Inc.	86
Abbott Laboratories	88
Admera Health, LLC	89
Agena Biosciences, Inc.	90
Astra Zeneca PLC	91
Bayer AG	92
Becton, Dickinson and Company	93
Cancer Genetics, Inc.	94
Dynamic DNA Laboratories	95
Empire Genomics LLC	96
F. Hoffmann-La Roche Ltd	97
geneOmbio Technologies Pvt Ltd.	98
Genomic Health, Inc.	99
Illumina, Inc.	100
Laboratory Corporation of America Holdings	101
Myriad Genetics Inc.	102
Oneome LLC	103
Opko Health, Inc.	104
Pathway Genomics Corporation	105
QIAGEN N.V.	106
Quest Diagnostics Incorporated	107
Teva Pharmaceuticals Industries Ltd.	108
Thermo Fisher Scientific Inc.	109
Transgenomic, Inc.	110
9 Investing in North America Market: Risk Assessment and Management	111
9.1 Risk Evaluation of North America Market	111
9.2 Critical Success Factors (CSFs)	114
Related Reports and Products	117
?

List Of Tables

Table 1.  Snapshot of North America Pharmacogenomics Market, 2019-2030	18
Table 2. Web-based Resources of Pharmacogenomics	23
Table 3.  Main Product Trends and Market Opportunities in North America Pharmacogenomics Market	33
Table 4. North America Pharmacogenomics Market by Service, 2019-2030, $ mn	41
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing	46
Table 6. North America Pharmacogenomics Market by Technology, 2019-2030, $ mn	48
Table 7. North America Pharmacogenomics Market by Application, 2019-2030, $ mn	56
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry	61
Table 9. North America Pharmacogenomics Market by End User, 2019-2030, $ mn	65
Table 10. North America Pharmacogenomics Market by Country, 2019-2030, $ mn	71
Table 11. U.S. Pharmacogenomics Market by Service, 2019-2030, $ mn	75
Table 12. U.S. Pharmacogenomics Market by Technology, 2019-2030, $ mn	75
Table 13. U.S. Pharmacogenomics Market by Application, 2019-2030, $ mn	75
Table 14. Canada Pharmacogenomics Market by Service, 2019-2030, $ mn	78
Table 15. Canada Pharmacogenomics Market by Technology, 2019-2030, $ mn	78
Table 16. Canada Pharmacogenomics Market by Application, 2019-2030, $ mn	78
Table 17. Mexico Pharmacogenomics Market by Service, 2019-2030, $ mn	80
Table 18. Mexico Pharmacogenomics Market by Technology, 2019-2030, $ mn	80
Table 19. Mexico Pharmacogenomics Market by Application, 2019-2030, $ mn	80
Table 20. Product Approvals by Company, January 2016 – April 2019	83
Table 21. Breakdown of North America Market by Key Vendor, 2019, %	83
Table 22. 23andMe, Inc.: Company Snapshot	86
Table 23. 23andMe, Inc.: Business Segmentation	86
Table 24. 23andMe, Inc.: Product Portfolio	87
Table 25. 23andMe, Inc.: Revenue, 2016-2018, $ mn	87
Table 26. 23andMe, Inc.: Recent Developments	87
Table 27.  Risk Evaluation for Investing in North America Market, 2019-2030	112
Table 28. Critical Success Factors and Key Takeaways	115

List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. North America Pharmacogenomics Market, 2019-2030, $ mn	20
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice	22
Figure 7. Impact of COVID-19 on Business	24
Figure 8. Primary Drivers and Impact Factors of North America Pharmacogenomics Market	26
Figure 9. World Top 10 Causes of Deaths, 2016	29
Figure 10. Primary Restraints and Impact Factors of North America Pharmacogenomics Market	30
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics	32
Figure 12. Investment Opportunity Analysis	34
Figure 13. Porter’s Fiver Forces Analysis of North America Pharmacogenomics Market	37
Figure 14. Breakdown of North America Pharmacogenomics Market by Service, 2019-2030, % of Revenue	41
Figure 15. North America Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)	42
Figure 16. North America Pharmacogenomics Market: Genotyping, 2019-2030, $ mn	43
Figure 17. North America Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn	44
Figure 18. North America Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn	45
Figure 19. North America Pharmacogenomics Market: Other Services, 2019-2030, $ mn	47
Figure 20. Breakdown of North America Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue	48
Figure 21. North America Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)	49
Figure 22. North America Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn	50
Figure 23. North America Pharmacogenomics Market: Microarray, 2019-2030, $ mn	51
Figure 24. North America Pharmacogenomics Market: Sequencing, 2019-2030, $ mn	52
Figure 25. North America Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn	53
Figure 26. North America Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn	54
Figure 27. North America Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn	55
Figure 28. Breakdown of North America Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue	56
Figure 29. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)	57
Figure 30. North America Pharmacogenomics Market: Oncology, 2019-2030, $ mn	58
Figure 31. North America Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn	59
Figure 32. North America Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn	60
Figure 33. North America Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn	62
Figure 34. North America Pharmacogenomics Market: Pain Management, 2019-2030, $ mn	63
Figure 35. North America Pharmacogenomics Market: Other Applications, 2019-2030, $ mn	64
Figure 36. Breakdown of North America Pharmacogenomics Market by End User, 2019-2030, % of Revenue	65
Figure 37. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)	66
Figure 38. North America Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn	67
Figure 39. North America Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn	68
Figure 40. North America Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn	69
Figure 41. Breakdown of North America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue	71
Figure 42. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)	72
Figure 43. U.S. Pharmacogenomics Market, 2019-2030, $ mn	74
Figure 44. Canada Pharmacogenomics Market, 2019-2030, $ mn	77
Figure 45.  Pharmacogenomics Market in Mexico, 2015-2030, $ mn	79
Figure 46. Growth Stage of North America Pharmacogenomics Industry over the Forecast Period	81

Key Players (this may not be a complete list and extra companies can be added upon request): 
3M Health Care Limited 
Adherium Limited 
Amiko Digital Health Limited 
AsthmaMD 
AstraZeneca plc 
Boehringer Ingelheim International GmbH 
Capsule Technologies, Inc. 
Cohero Health 
GlaxoSmithKline plc 
Kaia Health Software GmbH 
Medical International Research (MIR) 
Novartis AG 
NuvoAir 
Reciprocal Labs (Propeller Health) 
Sensiron AG 
Tactio Health 
Teva Pharmaceuticals Industries Ltd.